CONDYLOX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Condylox, and when can generic versions of Condylox launch?
Condylox is a drug marketed by Allergan and Teva Branded Pharm and is included in two NDAs.
The generic ingredient in CONDYLOX is podofilox. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the podofilox profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Condylox
A generic version of CONDYLOX was approved as podofilox by PADAGIS US on January 29th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CONDYLOX?
- What are the global sales for CONDYLOX?
- What is Average Wholesale Price for CONDYLOX?
Summary for CONDYLOX
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 123 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,620 |
| Drug Prices: | Drug price information for CONDYLOX |
| What excipients (inactive ingredients) are in CONDYLOX? | CONDYLOX excipients list |
| DailyMed Link: | CONDYLOX at DailyMed |
Recent Clinical Trials for CONDYLOX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hyloris Developments SA | Phase 3 |
| bioRASI, LLC | Phase 3 |
| Dermax SA | Phase 3 |
Pharmacology for CONDYLOX
| Physiological Effect | Decreased Mitosis |
US Patents and Regulatory Information for CONDYLOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | CONDYLOX | podofilox | GEL;TOPICAL | 020529-001 | Mar 13, 1997 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Branded Pharm | CONDYLOX | podofilox | SOLUTION;TOPICAL | 019795-001 | Dec 13, 1990 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CONDYLOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | CONDYLOX | podofilox | GEL;TOPICAL | 020529-001 | Mar 13, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Allergan | CONDYLOX | podofilox | GEL;TOPICAL | 020529-001 | Mar 13, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CONDYLOX
See the table below for patents covering CONDYLOX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 81190 | PROCESSO PARA O ISOLAMENTO E PURIFICACAO DE PODOFILOTOXINA | ⤷ Sign Up |
| Poland | 255527 | ⤷ Sign Up | |
| Poland | 147999 | ⤷ Sign Up | |
| Spain | 8702395 | ⤷ Sign Up | |
| Spain | 8900110 | ⤷ Sign Up | |
| Canada | 1276110 | PROCEDE POUR L'IDOLEMENT ET LA PURIFICATION DE PODOPHYLLOTOXINE (PROCESS FOR THE ISOLATION AND PURIFICATION OF PODOPHYLLOTOXIN) | ⤷ Sign Up |
| Spain | 555039 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
